权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel proteolytic mechanisms driving pathologic hepatic congestion in drug-induced hepatotoxicity

药物引起的肝毒性中驱动病理性肝充血的新蛋白水解机制

基本信息

批准号：
10638320
负责人：
Bryan L Copple
金额：
$ 49.79万
依托单位：
MICHIGAN STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-11 至 2027-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10638320
关键词：
Acetaminophen Acetylcysteine Active Sites Acute Liver Failure Agonist Analgesics Angiostatins Anti-Inflammatory Agents Automobile Driving Biochemistry Biological Markers Blood Vessels Blood coagulation Breeding Cell Separation Cells Complement Cytolysis Data Dose Elastases Enzyme Precursors Enzymes Equation Failure Fibrinolysis Flow Cytometry Generations Goals Hemorrhage Hepatic Hepatocyte Hepatotoxicity Hospital Costs Human Knockout Mice Leukocytes Life Link Liver Liver Dysfunction Liver Failure Liver diseases MME gene Macrophage Maps Mediating Modality Molecular Morbidity - disease rate Mus Mutation Nature Outcome Overdose Pathologic Pathology Pathway interactions Patients Peripheral Pharmaceutical Preparations Plasma Plasmin Plasminogen Prevention Production Proteins Proteolysis Proteomics Publishing Recommendation Recovery Regulation Research Risk Role Serine Protease Signal Pathway Site Small Interfering RNA System Testing Text Therapeutic Time United States Update Validation Vascular Diseases acetaminophen overdose acetaminophen-induced liver injury acute liver injury axl receptor tyrosine kinase cell type design drug induced liver injury experimental study extracellular genetic approach hepatoprotective hepatotoxin improved outcome inhibitor intrahepatic knock-down lipid nanoparticle liver injury liver repair mortality novel novel therapeutics pharmacologic prevent programs protective effect response thrombolysis vascular injury

项目摘要

Modified Project Summary/Abstract Section The summary/abstract did not require alteration The leading cause of acute liver injury and acute liver failure in the United States is hepatotoxicity caused by overdose of the pain medication acetaminophen (APAP). Even with available treatments (i.e., N-acetylcysteine), more than half of APAP overdose patients require costly hospitalization and antiquated standards to guide treatment. APAP overdose patients would benefit most from treatments that prevent the progression of simple hepatotoxicity to liver failure. Using robust experimental settings and results from acute liver failure patients, our team uncovered a novel pathway whereby macrophage elastase (MMP-12) prevents progression of hepatotoxicity to ALF by reducing excess production of the fibrinolytic enzyme plasmin. The current view is that plasmin production in the APAP-injured liver is controlled by standard proteins involved in blood clot lysis. However, our strong preliminary studies suggest that, in contrast to the current paradigm, hepatic plasmin generation is controlled locally by direct MMP-12-dependent proteolysis of the plasminogen zymogen. The central hypothesis framing these studies is macrophage elastase (MMP-12) prevents vascular damage and intrahepatic congestion after APAP overdose by cleaving plasminogen at a site that releases the anti-inflammatory factor angiostatin while preventing formation of active plasmin. Our approach includes genetically-modified mice with deficiency in components of the signaling pathway controlling MMP-12 expression, mice expressing plasminogen with an active site mutation that prevents plasmin activity, novel lipid nanoparticles to superimpose plasminogen deficiency in experimental APAP hepatotoxicity, and leading edge N-degradomics to pinpoint plasmin substrates in the injured liver. The established investigative team comprises experts in APAP-induced liver injury and repair, biochemistry/function of the fibrinolytic system, vascular pathology, leading-edge proteomic analysis, and experimental settings of liver disease. In our proposed studies we will: define the cellular and molecular mechanisms driving MMP-12 expression after acetaminophen overdose (Aim 1); determine the mechanisms whereby MMP-12 prevents pathologic vascular congestion in the acetaminophen-injured liver (Aim 2); and determine the role of plasmin(ogen) proteolytic and non-proteolytic functions in APAP-induced liver injury (Aim 3). The expected outcome of these Specific Aims is the discovery of a novel mechanistic link between leukocyte effector function (i.e., MMP-12 expression) and prevention of intrahepatic hyperfibrinolysis in the injured liver, including evidence of a novel molecular mechanism controlling plasmin generation. This could pinpoint mechanistic biomarkers to predict imminent hepatic vascular dysfunction in the injured liver and to uncover therapeutic modalities to prevent hepatic congestion after hepatotoxicant exposure. By virtue of separation from traditional regulation of fibrinolysis, this could greatly improve outcome in APAP overdose without increasing bleeding risk.

修改的项目摘要/摘要部分